{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,12,14]],"date-time":"2025-12-14T11:39:28Z","timestamp":1765712368433,"version":"3.48.0"},"reference-count":37,"publisher":"BMJ","issue":"8","funder":[{"DOI":"10.13039\/100009947","name":"Merck Sharp and Dohme","doi-asserted-by":"publisher","award":["53605"],"award-info":[{"award-number":["53605"]}],"id":[{"id":"10.13039\/100009947","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["bmj.com"],"crossmark-restriction":true},"short-container-title":["BMJ Open"],"accepted":{"date-parts":[[2019,7,2]]},"published-print":{"date-parts":[[2019,8]]},"abstract":"<jats:sec>\n                    <jats:title>Introduction<\/jats:title>\n                    <jats:p>Hepatitis C is a blood-borne virus (HCV) that can seriously damage the liver and is spread mainly through blood-to-blood contact with an infected person. Over 85% of individuals who have HCV in Scotland became infected following injecting drug use. Since people who inject drugs (PWID) are the main source of new infections, theoretical modelling has suggested that treatment of HCV infection in PWID may effectively reduce HCV prevalence and accomplish elimination. This protocol describes a clinical trial delivering HCV treatment within injecting equipment provision sites (IEPS) in Tayside, Scotland.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods and analysis<\/jats:title>\n                    <jats:p>\n                      PWID attending IEPS are tested for HCV and, if they are chronically infected with HCV and eligible, invited to receive treatment within the IEPS. They are randomised to one of three treatment regimens; daily observed treatment, treatment dispensed every 2 weeks and treatment dispensed every 2 weeks together with an adherence psychological intervention (administered before treatment begins). The primary outcome is comparison of the rate of successful treatment (SVR\n                      <jats:sub>12<\/jats:sub>\n                      ) in each treatment group. Secondary analyses include assessment of adherence, reinfection rates, viral resistance to treatment and interaction of the treatment with illicit drugs.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Ethics and dissemination<\/jats:title>\n                    <jats:p>The ADVANCE (A Direct obserVed therApy versus fortNightly CollEction) HCV trial was given favourable opinion by East of Scotland Research Ethics Committee (LR\/17\/ES\/0089) prior to commencement.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Trial registration numbers<\/jats:title>\n                    <jats:p>\n                      European Clinical Trials Database (EudraCT) (2017-001039-38) and ClinicalTrials.gov (\n                      <jats:ext-link xmlns:xlink=\"http:\/\/www.w3.org\/1999\/xlink\" ext-link-type=\"clintrialgov\" xlink:href=\"NCT03236506\">NCT03236506<\/jats:ext-link>\n                      ).\n                    <\/jats:p>\n                  <\/jats:sec>","DOI":"10.1136\/bmjopen-2019-029516","type":"journal-article","created":{"date-parts":[[2019,8,9]],"date-time":"2019-08-09T05:26:38Z","timestamp":1565328398000},"page":"e029516","update-policy":"https:\/\/doi.org\/10.1136\/crossmarkpolicy","source":"Crossref","is-referenced-by-count":9,"title":["Randomised controlled trial conducted in injecting equipment provision sites to compare the effectiveness of different hepatitis C treatment regimens in people who inject drugs: A Direct obserVed therApy versus fortNightly CollEction study for HCV treatment\u2014ADVANCE HCV protocol study"],"prefix":"10.1136","volume":"9","clinical-trial-number":[{"clinical-trial-number":"nct03236506","registry":"10.18810\/clinical-trials-gov"}],"author":[{"given":"Sarah K","family":"Inglis","sequence":"first","affiliation":[{"name":"Tayside Clinical Trials Unit, University of Dundee, Dundee, UK"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lewis JZ","family":"Beer","sequence":"additional","affiliation":[{"name":"Tayside Clinical Trials Unit, University of Dundee, Dundee, UK"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Christopher","family":"Byrne","sequence":"additional","affiliation":[{"name":"Tayside Clinical Trials Unit, University of Dundee, Dundee, UK"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Amy","family":"Malaguti","sequence":"additional","affiliation":[{"name":"School of Social Sciences (Psychology), University of Dundee, Dundee, UK"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Emma","family":"Robinson","sequence":"additional","affiliation":[{"name":"Molecular and Clinical Medicine, University of Dundee, Dundee, UK"},{"name":"Specialist liver service, NHS Tayside, Dundee, UK"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Christian","family":"Sharkey","sequence":"additional","affiliation":[{"name":"Specialist liver service, NHS Tayside, Dundee, UK"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kirsty","family":"Gillings","sequence":"additional","affiliation":[{"name":"Psychology Department, NHS Fife, Cupar, UK"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Brian","family":"Stephens","sequence":"additional","affiliation":[{"name":"Specialist liver service, NHS Tayside, Dundee, UK"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"John F","family":"Dillon","sequence":"additional","affiliation":[{"name":"Molecular and Clinical Medicine, University of Dundee, Dundee, UK"},{"name":"Specialist liver service, NHS Tayside, Dundee, UK"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"239","published-online":{"date-parts":[[2019,8,8]]},"reference":[{"key":"2025121403363313000_9.8.e029516.1","unstructured":"Organisation WH . Hepatitis C factsheet, 2018. Available: https:\/\/www.who.int\/news-room\/fact-sheets\/detail\/hepatitis-c"},{"key":"2025121403363313000_9.8.e029516.2","unstructured":"M C . Members' debate on hepatitis C. Edinburgh: Parliament S, 2004."},{"key":"2025121403363313000_9.8.e029516.3","doi-asserted-by":"publisher","DOI":"10.1258\/rsmsmj.51.1.8"},{"key":"2025121403363313000_9.8.e029516.4","unstructured":"Government S . Hepatitis C action plan for for Scotland phase II: may 2008-March 2011. Edinburgh, Scotland: Scottish Government, 2008."},{"key":"2025121403363313000_9.8.e029516.5","unstructured":"Scotland HI . National clinical guidelines for the treatment of HCV in adults V5 2018."},{"key":"2025121403363313000_9.8.e029516.6","unstructured":"Scotland HP . The needle exchange surveillance initiative: prevalence of blood-borne viruses and injecting risk behaviours among people who inject drugs attending injecting equipment provision services in Scotland, 2008-09 to 2015-16. Health Protection Scotland, University of the West of Scotland, Glasgow Caledonian University and the West of Scotland Specialist Virology Centre, 2017."},{"key":"2025121403363313000_9.8.e029516.7","doi-asserted-by":"publisher","DOI":"10.1017\/S0950268806007035"},{"key":"2025121403363313000_9.8.e029516.8","doi-asserted-by":"publisher","DOI":"10.1067\/mjd.2001.109311"},{"key":"2025121403363313000_9.8.e029516.9","doi-asserted-by":"crossref","unstructured":"O'Brien TR , Yang H-I , Groover S , et al . Genetic factors that affect spontaneous clearance of hepatitis C or B virus, response to treatment, and disease progression. Gastroenterology 2018.","DOI":"10.1053\/j.gastro.2018.09.052"},{"key":"2025121403363313000_9.8.e029516.10","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhep.2014.07.012"},{"key":"2025121403363313000_9.8.e029516.11","first-page":"154","article-title":"Direct-Acting antiviral medications for chronic hepatitis C virus infection","volume":"7","author":"Jazwinski","year":"2011","journal-title":"Gastroenterol Hepatol"},{"key":"2025121403363313000_9.8.e029516.12","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1016\/j.coviro.2017.03.017","article-title":"Direct-Acting antivirals: the endgame for hepatitis C?","volume":"24","author":"D'Ambrosio","year":"2017","journal-title":"Curr Opin Virol"},{"key":"2025121403363313000_9.8.e029516.13","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(11)60821-0"},{"key":"2025121403363313000_9.8.e029516.14","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0087872","article-title":"Expansion of HAART coverage is associated with sustained decreases in HIV\/AIDS morbidity, mortality and HIV transmission: the \"HIV Treatment as Prevention\" experience in a Canadian setting","volume":"9","author":"Montaner","year":"2014","journal-title":"PLoS One"},{"key":"2025121403363313000_9.8.e029516.15","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhep.2010.08.029"},{"key":"2025121403363313000_9.8.e029516.16","doi-asserted-by":"publisher","DOI":"10.1136\/gutjnl-2014-308166"},{"key":"2025121403363313000_9.8.e029516.17","doi-asserted-by":"publisher","DOI":"10.1002\/hep.20836"},{"key":"2025121403363313000_9.8.e029516.18","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhep.2014.05.008"},{"key":"2025121403363313000_9.8.e029516.19","doi-asserted-by":"crossref","first-page":"631","DOI":"10.1111\/jvh.12529","article-title":"New treatments for hepatitis C virus (HCV): scope for preventing liver disease and HCV transmission in England","volume":"23","author":"Harris","year":"2016","journal-title":"J Viral Hepat"},{"key":"2025121403363313000_9.8.e029516.20","doi-asserted-by":"publisher","DOI":"10.1111\/jvh.12008"},{"key":"2025121403363313000_9.8.e029516.21","doi-asserted-by":"publisher","DOI":"10.1089\/apc.2010.0142"},{"key":"2025121403363313000_9.8.e029516.22","doi-asserted-by":"crossref","first-page":"1072","DOI":"10.1016\/j.drugpo.2015.05.007","article-title":"Human rights and access to hepatitis C treatment for people who inject drugs","volume":"26","author":"Wolfe","year":"2015","journal-title":"Int J Drug Policy"},{"key":"2025121403363313000_9.8.e029516.23","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0216123","article-title":"On the way to hepatitis C elimination in the Republic of Georgia-Barriers and facilitators for people who inject drugs for engaging in the treatment program: a formative qualitative study","volume":"14","author":"Chikovani","year":"2019","journal-title":"PLoS One"},{"key":"2025121403363313000_9.8.e029516.24","doi-asserted-by":"crossref","DOI":"10.1136\/bmjopen-2017-021443","article-title":"Clinical effectiveness of pharmacy-led versus conventionally delivered antiviral treatment for hepatitis C in patients receiving opioid substitution therapy: a study protocol for a pragmatic cluster randomised trial","volume":"8","author":"Radley","year":"2018","journal-title":"BMJ Open"},{"key":"2025121403363313000_9.8.e029516.25","doi-asserted-by":"crossref","unstructured":"Schulkind J , Stephens B , Ahmad F , et al . High response and re-infection rates among people who inject drugs treated for hepatitis C in a community needle and syringe programme. J Viral Hepat 2018.","DOI":"10.1111\/jvh.13035"},{"key":"2025121403363313000_9.8.e029516.26","doi-asserted-by":"publisher","DOI":"10.1086\/521166"},{"key":"2025121403363313000_9.8.e029516.27","unstructured":"TCTU . Tayside clinical trials unit, 2014. Available: https:\/\/www.ahspartnership.org.uk\/tasc\/tayside-clinical-trials-unit"},{"key":"2025121403363313000_9.8.e029516.28","doi-asserted-by":"publisher","DOI":"10.1002\/hep.28877"},{"key":"2025121403363313000_9.8.e029516.29","unstructured":"Merck . Zepatier tolerability in clinical trials. Available: https:\/\/www.merckconnect.com\/zepatier\/adverse-reactions.html?hcpUser=yes"},{"key":"2025121403363313000_9.8.e029516.30","doi-asserted-by":"crossref","unstructured":"Sagnelli E , Starace M , Minichini C , et al . Resistance detection and re-treatment options in hepatitis C virus-related chronic liver diseases after DAA-treatment failure. Infection 2018.","DOI":"10.1007\/s15010-018-1188-3"},{"key":"2025121403363313000_9.8.e029516.31","doi-asserted-by":"publisher","DOI":"10.1037\/0278-6133.25.4.462"},{"key":"2025121403363313000_9.8.e029516.32","doi-asserted-by":"crossref","first-page":"e41","DOI":"10.1097\/MCG.0000000000000151","article-title":"Adherence during antiviral treatment regimens for chronic hepatitis C: a qualitative study of patient-reported facilitators and barriers","volume":"49","author":"Evon","year":"2015","journal-title":"J Clin Gastroenterol"},{"key":"2025121403363313000_9.8.e029516.33","doi-asserted-by":"publisher","DOI":"10.1037\/0022-0167.40.4.385"},{"key":"2025121403363313000_9.8.e029516.34","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1402454"},{"key":"2025121403363313000_9.8.e029516.35","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1613512"},{"key":"2025121403363313000_9.8.e029516.36","doi-asserted-by":"publisher","DOI":"10.1002\/hep.29081"},{"key":"2025121403363313000_9.8.e029516.37","unstructured":"OpenClinica . OpenClinica open source for clinical research. Available: https:\/\/openclinica.com\/"}],"container-title":["BMJ Open"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1136\/bmjopen-2019-029516","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,12,14]],"date-time":"2025-12-14T11:36:40Z","timestamp":1765712200000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmjopen.bmj.com\/lookup\/doi\/10.1136\/bmjopen-2019-029516"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,8]]},"references-count":37,"journal-issue":{"issue":"8","published-online":{"date-parts":[[2019,8,8]]},"published-print":{"date-parts":[[2019,8]]}},"alternative-id":["10.1136\/bmjopen-2019-029516"],"URL":"https:\/\/doi.org\/10.1136\/bmjopen-2019-029516","relation":{},"ISSN":["2044-6055","2044-6055"],"issn-type":[{"type":"print","value":"2044-6055"},{"type":"electronic","value":"2044-6055"}],"subject":[],"published":{"date-parts":[[2019,8]]}}}